---
title: "VIVA BIOTECH's incubated enterprise investment received a merger and acquisition with a maximum cost of 47 million USD"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/269625089.md"
description: "VIVA BIOTECH announced that its 3.14% stake in Arthrosi Therapeutics has been acquired by Sobi US Holding Corp., with a total transaction price of up to $47 million. The company expects to receive an initial payment of approximately $30 million and contingent consideration not exceeding $17 million, estimating a realized gain of about $4 million. After the acquisition is completed, VIVA BIOTECH will no longer hold equity in Arthrosi Therapeutics"
datetime: "2025-12-14T11:28:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269625089.md)
  - [en](https://longbridge.com/en/news/269625089.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269625089.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/269625089.md) | [English](https://longbridge.com/en/news/269625089.md)


# VIVA BIOTECH's incubated enterprise investment received a merger and acquisition with a maximum cost of 47 million USD

VIVA BIOTECH (01873.HK) announced that its 3.14% stake in Arthrosi Therapeutics has been acquired by Sobi US Holding Corp. through a merger, with an upfront payment of USD 950 million and contingent consideration of up to USD 550 million. The group expects to receive an initial payment of approximately USD 30 million and contingent consideration of up to USD 17 million, estimating a fair value gain of approximately USD 4 million.

Upon completion, the company will no longer hold any equity in Arthrosi Therapeutics, which is a clinical-stage biotechnology company

### 相關股票

- [VIVA BIOTECH (01873.HK)](https://longbridge.com/zh-HK/quote/01873.HK.md)

## 相關資訊與研究

- [VIVA Biotech Investors Suspend Repurchase Rights for Shanghai VIVA Equity](https://longbridge.com/zh-HK/news/271493678.md)
- [08:33 ETInc. Names Interstate to Its 'Fastest-Growing in the Mid-Atlantic' List](https://longbridge.com/zh-HK/news/281524757.md)
- [Nomura Upgrades Angelalign Technology to Buy From Neutral, Adjusts Price Target to HK$79.89 From HK$66.71](https://longbridge.com/zh-HK/news/281138646.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-HK/news/280997570.md)
- [CATL's controlling shareholder to donate some A-shares](https://longbridge.com/zh-HK/news/281197776.md)